PPAR agonists have antiinflammatory activity, are approved as treatments for insulin resistance in diabetes and hyperlipidemia (149), and show promise as immune therapies for AD and other central nervous system diseases (150). This evidence concerns the gene PPARA and hyperlipidemia.